Recent Articles
Weekly Psychedelic Policy Briefing: September 30th, 2026
DEA proposed placing five tryptamines in Schedule I, including the active compound in a postpartum depression drug FDA designated a breakthrough therapy in February. Oregon dropped its psilocybin fee hikes, and a GAO audit found DEA and FDA have no written procedures for how scheduling decisions get made.
By Jack Gorsline
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity
By Jack Gorsline
Filter
What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics
Reuters attributed a quote about access and reimbursement to Lynn Watkins at Monday’s FDA hearing…
By Joe Moore
Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans
Veterans built the psychedelic policy movement in state legislatures. This year, firefighters, police officers, and…
By Logan Davidson
The Best Psychedelic Education Does Not Look Psychedelic
Devon Phillips, partnerships manager at MAPS, argues that people rarely change because they got better…
By Devon Phillips
Who Gets to Heal?
A donor gift with no diagnosis requirement forced a debate inside Thank You Life. Its…
By Meredith Thomas
Weekly Psychedelic Policy Briefing: August 23, 2026
Oregon’s psilocybin program posted its first real-world outcome data this week, just as regulators move…
By Jack Gorsline
Weekly Psychedelic Policy Briefing – August 16, 2026
Resilient Pharmaceuticals has resubmitted its New Drug Application for MDMA-assisted therapy for PTSD, without the…